
CRSP • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold CRSP in your mock portfolio yet.
Crispr Therapeutics remains unprofitable, as reflected in its negative EPS and PE ratio. The current earnings profile suggests the business is still in a heavy investment and R&D phase, with no clear line-of-sight to consistent profitability based on the data provided. This keeps the equity story highly dependent on future clinical and regulatory milestones rather than current financial strength.
The stock is trading at $49.96, down 7.1% over the last month and below its 200-day moving average of $53.26, signaling a weak intermediate trend. However, an RSI of 33.17 is approaching oversold territory, suggesting that near-term downside momentum may be slowing and a technical rebound is possible. Overall, the setup looks more like a consolidation or correction within a high-volatility biotech name rather than a clear breakdown or uptrend.
Web traffic of roughly 111,567 visitors per month suggests a moderate level of ongoing interest, but no explosive growth is indicated. Social media followings on Twitter/X and LinkedIn are inching higher, pointing to slowly improving awareness and professional engagement. The 30.8% month-over-month decline in job openings, however, may signal a more cautious hiring stance, which could reflect cost discipline or a more conservative near-term growth outlook.
Crispr Therapeutics presents a mixed picture: structurally unprofitable today, with a stock that has recently weakened but is nearing oversold technical levels, and alternative data that show modest engagement but no strong acceleration. The investment case remains heavily dependent on future clinical and commercial execution rather than current financial strength. Overall, the signals tilt toward a neutral stance, with elevated risk but potential upside if pipeline milestones or sentiment improve.


CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Crispr Therapeutics: Very High Risk But Even Higher Potential Reward

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: